Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.
Tolaney SM, Guarneri V, Seo JH, Cruz J, Abreu MH, Takahashi M, Barrios C, McIntyre K, Wei R, Munoz M, Antonio BS, Liepa AM, Martin M, Johnston SRD, Kellokumpu-Lehtinen PL, Harbeck N.
Tolaney SM, et al. Among authors: abreu mh.
Eur J Cancer. 2024 Mar;199:113555. doi: 10.1016/j.ejca.2024.113555. Epub 2024 Jan 16.
Eur J Cancer. 2024.
PMID: 38244363
Free article.